Search research articles
Contact Us
Filters
Showing results (11-20 of 27) with videos related to
Page
of 3
Sort By:
Oncogene
|
September 12, 2024
AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer
Sumaira Sardar, Christopher M McNair, Lakshmi Ravindranath, et al.
Investigational New Drugs
|
May 15, 2026
A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancer
Khobe Chandran, Christina Guo, Simon Pacey, et al.
Iscience
|
December 24, 2025
Developing therapeutic strategies to target MCL1 and BCLXL in lethal prostate cancer
Daniel Westaby, Juan M Jiménez-Vacas, Ines Figueiredo, et al.
Cancer Discovery
|
April 21, 2021
RB/E2F1 as a Master Regulator of Cancer Cell Metabolism in Advanced Disease
Amy C Mandigo, Wei Yuan, Kexin Xu, et al.
The Journal of Clinical Investigation
|
June 4, 2024
RNASEH2B loss and PARP inhibition in advanced prostate cancer
Juliet Carmichael, Ines Figueiredo, Bora Gurel, et al.
European Urology
|
March 24, 2023
Erratum to "B7-H3 as a Therapeutic Target in Advanced Prostate Cancer" [Eur Urol 2023;83(3):224-38]
Christina Guo, Ines Figueiredo, Bora Gurel, et al.
European Urology
|
September 16, 2022
B7-H3 as a Therapeutic Target in Advanced Prostate Cancer
Christina Guo, Ines Figueiredo, Bora Gurel, et al.
Cancer Cell
|
November 22, 2024
Elucidating acquired PARP inhibitor resistance in advanced prostate cancer
George Seed, Nick Beije, Wei Yuan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 13, 2022
Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer
Adam G Sowalsky, Ines Figueiredo, Rosina T Lis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 27, 2026
Phase I trial of Ipatasertib plus Atezolizumab enhances PI3K/AKT pathway immune responses in solid tumors and refractory glioblastoma
Crescens Tiu, Wing Yau, Diogo Silva, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 27) with videos related to
Sort By:
Page
of 3
Oncogene
|
September 12, 2024
AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer
Sumaira Sardar, Christopher M McNair, Lakshmi Ravindranath, et al.
Investigational New Drugs
|
May 15, 2026
A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancer
Khobe Chandran, Christina Guo, Simon Pacey, et al.
Iscience
|
December 24, 2025
Developing therapeutic strategies to target MCL1 and BCLXL in lethal prostate cancer
Daniel Westaby, Juan M Jiménez-Vacas, Ines Figueiredo, et al.
Cancer Discovery
|
April 21, 2021
RB/E2F1 as a Master Regulator of Cancer Cell Metabolism in Advanced Disease
Amy C Mandigo, Wei Yuan, Kexin Xu, et al.
The Journal of Clinical Investigation
|
June 4, 2024
RNASEH2B loss and PARP inhibition in advanced prostate cancer
Juliet Carmichael, Ines Figueiredo, Bora Gurel, et al.
European Urology
|
March 24, 2023
Erratum to "B7-H3 as a Therapeutic Target in Advanced Prostate Cancer" [Eur Urol 2023;83(3):224-38]
Christina Guo, Ines Figueiredo, Bora Gurel, et al.
European Urology
|
September 16, 2022
B7-H3 as a Therapeutic Target in Advanced Prostate Cancer
Christina Guo, Ines Figueiredo, Bora Gurel, et al.
Cancer Cell
|
November 22, 2024
Elucidating acquired PARP inhibitor resistance in advanced prostate cancer
George Seed, Nick Beije, Wei Yuan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 13, 2022
Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer
Adam G Sowalsky, Ines Figueiredo, Rosina T Lis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 27, 2026
Phase I trial of Ipatasertib plus Atezolizumab enhances PI3K/AKT pathway immune responses in solid tumors and refractory glioblastoma
Crescens Tiu, Wing Yau, Diogo Silva, et al.
Page
of 3